Competitor Analysis: EGF-R Agonists and Antagonists

Table of Contents

2008 Sales of EGF-R Antagonists

EGF-R Agonists

Erbitux Pipeline

Biologics as EGF-R Antagonists

Selective EGF Receptor Antagonists

Dual EGF-R and Her2-R Antagonists

Pan-ErbB (pan-Her) Receptor Antagonists

Multi-Target EGF-R Antagonists

Corporate EGF-R Agonists and Antagonists R&D Pipelines

• Abbott
• Ambit Biosciences
• Amgen
• Array BioPharma
• AstraZeneca
• Attenuon
• Aveo Pharmaceuticals
• Avila Therapeutics
• Bharat Biotech International
• Biocon
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMD)
• Celldex Therapeutics
• Chugai
• Curis
• Daewoong Pharmaceutical Co.
• Daiichi Sankyo
• DxS
• Eli Lilly
• Genentech
• Genmab
• GlaxoSmithKline (GSK)
• GlobeImmune
• Hana Biosciences
• InNexus Biotechnology
• ISU Abxis
• Jennerex Biotherapeutics
• Life Science Pharmaceuticals
• Med Discovery
• Medarex
• Merck Serono
• Micromet
• Oncalis
• Oncoscience
• Osi Pharmaceuticals
• Pfizer
• Roche
• Scancell
• Shantha Biotechnics
• Shionogi
• Symphogen
• Takeda Pharmaceutical Co.
• Transition Therapeutics
• Uni-Bio Science Group
• Xencor
• YM Biosciences
• Zenotech Laboratories
• ZymoGenetics